August 4, 2022
Life Sciences
  • A federal court jury ordered Eli Lilly to pay $61 million to settle charges that it intentionally skimped on payments for the Medicaid drug rebate program. The company’s failure to pay allegedly resulted in losses for the federal government program and Medicaid agencies across 26 states. Eli Lilli & Co. announced that it will start commercially selling its COVID-19 monoclonal antibody treatment to states, health systems and other providers on August 15. The move comes as the federal government’s supply of bebtelovimab is close to running out. (Articles here and here)